Navigation Links
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
Date:6/18/2009

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Florida corporation, announce the signature of an exclusive license agreement for the development and commercialization of Debio 0928, a small molecule in early preclinical development that inhibits the protein-protein interaction between Raf-1 (key signalling kinase in the MAP kinase pathway) and Rb (retinoblastoma protein). Rb acts as a barrier to cell division and proliferation. However, when Raf-1 physically interacts with Rb, it triggers a cascade of signals that eventually overcomes this barrier, thus inducing cellular proliferation. By preventing the interaction between Raf-1 and Rb and blocking the cell cycle, Debio 0928 creates a new strategy in the fight against cancer and is thus a potentially promising novel anti-tumour drug.

Under the terms of the agreement, Debiopharm shall pay Moffitt an up-front fee, as well as predefined advanced milestone payments during the development of Debio 0928. First entry of the product into man is expected for 2012.

"This discovery, made by the collaboration between Drs. Srikumar Chellappan, Said Sebti, and Nicholas Lawrence at Moffitt, is a novel approach to the treatment of cancer," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "Being able to de-activate a key signalling kinase like Raf-1, known to be involved in many types of cancer, could open the door to more effective oncology treatments in the future."

"The disruption of the binding of the tumour promoter Raf-1 to the tumour suppressor Rb with Debio 0928 is a novel, first-in-class therapeutic strategy that has the potential for targeting a wide spectrum of human cancers," added
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
5. Debiopharm and EPFL Establish an Oncology Chair
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Digital Healthcare Specialist Cadient Group Ranked #2 on List of Full-service Advertising Agencies in the Philadelphia Region
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. Cadient Group Brings Home the Gold and Two Bronze Aster Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/13/2014)... 2014 Clarassance, a privately held clinical-stage ... name: Therabron Therapeutics , Inc. The new name ... type of structure in the lungs similar to branches ... develop novel protein therapeutics for the treatment of respiratory ... change the name to mark the company's escalation into ...
(Date:12/13/2014)... New York (PRWEB) December 13, 2014 ... its global network and Cold Chain capabilities, and is ... Tower in Paris, France, to serve Life Science clients ... facility equipped with a controlled-ambient warehouse, will provide 24/7 ... for vaccines and investigational drugs, patient-clinical specimens, API, following ...
(Date:12/12/2014)... InSphero AG, the world’s leading provider of ... that data presented recently by Genentech (South San Francisco, ... predictive model system for assessment of liver toxicity. ... Functional Analysis and Screening Technologies (FAST) Congress summarized ... 3D InSight™ Human Liver Microtissues to 42 ...
Breaking Biology Technology:AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
... One of,Brazil,s leading distributors of pharmaceutical products, Profarma,Distribuidora de Produtos ... its results for the fourth quarter of,2007 (4Q07) and full ... Profarma,s market share breaks record and reaches 12.8% which is ... reached in the 3Q07 and 3.2 ...
... Reports Problems in VA System for Veterans with ... Kilpatrick,Ph.D., MUSC distinguished university professor and director of ... MUSC,s Institute of,Psychiatry, testified before Congress Feb 26 ... the PTSD (post-traumatic stress disorder) Compensation Committee,regarding findings ...
... ... 2007 Highlights: * Product revenues increased 29% ... units increase 20% to 116,300 units, IRVINE, Calif., Feb. 26 Masimo ... Perfusion pulse oximetry, today announced its financial,results for both the quarter and year ...
Cached Biology Technology:MUSC's Kilpatrick to Address Congress Regarding PTSD Care 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12
(Date:11/18/2014)... --  News Highlights: , ... Partners Data Lake, an agile data and analytics ... allow researcher and clinicians to explore and develop ... of patients , The Partners Data Lake ... Partners system, breaking down physical barriers for collaboration ...
(Date:11/12/2014)... BEACH GARDENS, Fla. , Nov. 12, 2014 /PRNewswire/ ... solutions, announced today that its U.are.U ® fingerprint ... retail bakery chain in Central Mexico ... in June 2014 to eliminate payroll issues caused by ... Prior to installing the U.are.U fingerprint readers, Montparnasse relied ...
(Date:11/7/2014)... Nov. 7, 2014  In conjunction with the ... Departments, The Community Foundation of the Verdugos has announced the ... JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo Regional ... its first six months of existence, the Lab has processed ... for local law enforcement. "Because our number one ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... Hopkins undergraduates have invented a device to improve cell ... inside a major blood vessel. , A team ... Hopkins doctors and engineers, devised a protective "pouch" that ... the liver. This pouch would keep microcapsules of therapeutic ...
... and number of species crystallized into a mathematical power ... as biological destinations where species from large continents arrive ... seclusion. , Since islands have many times fewer ... continents were rich sources from which islands drew only ...
... percent, yet there is a considerable difference in the mental ... showed that a certain form of neuropsin, a protein that ... in the central nervous systems of humans and that it ... also demonstrated the molecular mechanism that creates this novel protein, ...
Cached Biology News:Students invent protective pouch to enhance cell therapy 2Students invent protective pouch to enhance cell therapy 3Students invent protective pouch to enhance cell therapy 4Invasion of the island bats 2Gene mutation linked to cognition is found only in humans 2
... tetrasodium bromide), 50mg/vial. MTT is a pale ... cells to yield a dark blue formazan ... even freshly dead cells do not cleave ... a component of Chemicons MTT assay kit, ...
... Infinite 200 series of microplate readers combines ... detection in an affordable, easy-to-use platform for ... The unique modular design and adaptability of ... a choice of a monochromator (M200) or ...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
Biology Products: